Bonus Financial Statements From 2010 to 2024
| BBIXF Stock | USD 0.02 0.00 0.00% |
Check Bonus BioGroup financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bonus BioGroup's main balance sheet or income statement drivers, such as , as well as many indicators such as . Bonus financial statements analysis is a perfect complement when working with Bonus BioGroup Valuation or Volatility modules.
Bonus |
Bonus BioGroup Company Shares Outstanding Analysis
Bonus BioGroup's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Bonus BioGroup Shares Outstanding | 1.17 B |
Most of Bonus BioGroup's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bonus BioGroup is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Bonus BioGroup has 1.17 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is 104.25% lower than that of the firm.
Bonus BioGroup Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bonus BioGroup's current stock value. Our valuation model uses many indicators to compare Bonus BioGroup value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bonus BioGroup competition to find correlations between indicators driving Bonus BioGroup's intrinsic value. More Info.Bonus BioGroup is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bonus BioGroup's earnings, one of the primary drivers of an investment's value.About Bonus BioGroup Financial Statements
Bonus BioGroup stakeholders use historical fundamental indicators, such as Bonus BioGroup's revenue or net income, to determine how well the company is positioned to perform in the future. Although Bonus BioGroup investors may analyze each financial statement separately, they are all interrelated. For example, changes in Bonus BioGroup's assets and liabilities are reflected in the revenues and expenses on Bonus BioGroup's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Bonus BioGroup. Please read more on our technical analysis and fundamental analysis pages.
Bonus BioGroup Ltd., a biotechnology company, develops technology solutions to generate tissue-regenerating bone grafts. Bonus BioGroup Ltd. was founded in 1981 and is based in Haifa, Israel. Bonus Biogroup is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Bonus Pink Sheet
Bonus BioGroup financial ratios help investors to determine whether Bonus Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bonus with respect to the benefits of owning Bonus BioGroup security.